12:00 AM
Nov 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III HELIOS trial in 743 patients showed that once-daily 500 ug oral Daxas plus Spiriva tiotropium for 24 weeks significantly improved breathlessness as measured by a reduction from baseline in Shortness of Breath Questionnaire (SOBQ) total score vs. placebo plus Spiriva (p=0.005). Data were presented at the American College of Chest Physicians meeting in San Diego. Nycomed previously reported that Daxas met the primary...

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >